SG/CALL/MODERNA/160/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 03:41:27 2024-05-10 pm EDT | ||
| 0.36 EUR | -25.00% |
|
| Current month | -2.70% | ||
| 3 months | +71.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.36 | -25.00% | 0 |
| 24-05-09 | 0.48 | +6.67% | 0 |
| 24-05-08 | 0.45 | +2.27% | 0 |
| 24-05-07 | 0.44 | -8.33% | 0 |
| 24-05-06 | 0.48 | -15.79% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 10, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ80AU |
| ISIN | DE000SQ80AU3 |
| Date issued | 2023-02-13 |
| Strike | 160 $ |
| Maturity | 2024-09-20 (132 Days) |
| Parity | 10 : 1 |
| Emission price | 4.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.7 € |
|---|---|
| Lowest since issue | 0.16 € |
| Spread | 0.01 € |
| Spread % | 2.78% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant